Document Detail

Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes.
MedLine Citation:
PMID:  18804761     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: According to data from animal models, complement activation plays a major role in the brain injury after acute ischemic stroke. Scarce findings are, however, available on the detection of complement activation products in stroke patients. METHODS: We have measured plasma levels of the five complement activation products (C1rC1sC1inh, C4d, C3a, C5a and SC5b-9) in samples of 26 patients with ischemic stroke upon admission. Twenty-six patients with severe carotid atherosclerosis served as patient controls. RESULTS: Levels of two activation products (SC5b-9 and C4d)) were significantly elevated in the plasma of stroke patients, SC5b-9 levels, exhibited significant positive correlation with the clinical severity of stroke, the severity of neurological deficit, as well as with the level of functional disability. CONCLUSION: These findings suggest that complement activation plays an active role in the development of brain infarct. The measurement of complement activation products might help to determine the clinical prognosis after acute ischemic stroke. Furthermore, there is potential usefulness of complement modulating therapy in ischemic stroke.
Gábor Széplaki; Róbert Szegedi; Kristóf Hirschberg; Tímea Gombos; Lilian Varga; István Karádi; László Entz; Zoltán Széplaki; Peter Garred; Zoltán Prohászka; George Füst
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-08-14
Journal Detail:
Title:  Atherosclerosis     Volume:  204     ISSN:  1879-1484     ISO Abbreviation:  Atherosclerosis     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-05-04     Completed Date:  2009-08-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  315-20     Citation Subset:  IM    
3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Biological Markers / blood
Brain Ischemia / complications,  genetics,  immunology*
C-Reactive Protein / metabolism
Case-Control Studies
Cerebral Infarction / diagnosis,  genetics,  immunology*
Complement Activation*
Complement C1 Inactivator Proteins / metabolism
Complement C1r / metabolism
Complement C3a / metabolism
Complement C4b
Complement C5a / metabolism
Complement Membrane Attack Complex / metabolism
Disability Evaluation
Mannose-Binding Lectin / genetics
Middle Aged
Peptide Fragments / blood
Severity of Illness Index
Stroke / diagnosis,  genetics,  immunology*
Time Factors
Reg. No./Substance:
0/Biological Markers; 0/Complement C1 Inactivator Proteins; 0/Complement Membrane Attack Complex; 0/MBL2 protein, human; 0/Mannose-Binding Lectin; 0/Peptide Fragments; 0/SC5b-9 protein complex; 0/SERPING1 protein, human; 80295-42-7/Complement C3a; 80295-50-7/Complement C4b; 80295-52-9/complement C4d; 80295-54-1/Complement C5a; 9007-41-4/C-Reactive Protein; EC C1r

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic ...
Next Document:  Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes...